Targeting Vascular Normalization: a Promising Strategy to Improve Immune-vascular Crosstalk in Cancer Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jan 9

PMID 38193080

Authors

Cheng Qian

Chaoqun Liu

Weiwei Liu

Rui Zhou

Liang Zhao

Affiliations

Soon will be listed here.

Abstract

Blood vessels are a key target for cancer therapy. Compared with the healthy vasculature, tumor blood vessels are extremely immature, highly permeable, and deficient in pericytes. The aberrantly vascularized tumor microenvironment is characterized by hypoxia, low pH, high interstitial pressure, and immunosuppression. The efficacy of chemotherapy, radiotherapy, and immunotherapy is affected by abnormal blood vessels. Some anti-angiogenic drugs show vascular normalization effects in addition to targeting angiogenesis. Reversing the abnormal state of blood vessels creates a normal microenvironment, essential for various cancer treatments, specifically immunotherapy. In addition, immune cells and molecules are involved in the regulation of angiogenesis. Therefore, combining vascular normalization with immunotherapy may increase the efficacy of immunotherapy and reduce the risk of adverse reactions. In this review, we discussed the structure, function, and formation of abnormal vessels. In addition, we elaborated on the role of the immunosuppressive microenvironment in the formation of abnormal vessels. Finally, we described the clinical challenges associated with the combination of immunotherapy with vascular normalization, and highlighted future research directions in this therapeutic area.

Citing Articles

Lipid Nanoparticle Delivery System for Normalization of Tumor Microenvironment and Tumor Vascular Structure.

Ha H, Choi Y, Kim N, Kim J, Jang J, Niepa T Biomater Res. 2025; 29:0144.

PMID: 39935791 PMC: 11811622. DOI: 10.34133/bmr.0144.

Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist.

Magdalena J, Justyna C, Joanna C, Ryszard S, Alina D, Dorota S Cancer Immunol Immunother. 2025; 74(3):90.

PMID: 39891776 PMC: 11787066. DOI: 10.1007/s00262-025-03943-2.

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Subverting to Prevent : Alteration of Effector Immune Cell Migration and Adhesion as a Key Mechanism of Tumor Immune Evasion.

Mastrogiovanni M, Donnadieu E, Pathak R, Di Bartolo V Biology (Basel). 2024; 13(11).

PMID: 39596815 PMC: 11591779. DOI: 10.3390/biology13110860.

The influence of endothelial metabolic reprogramming on the tumor microenvironment.

Kane K, Edwards D, Chen J Oncogene. 2024; 44(2):51-63.

PMID: 39567756 PMC: 11706781. DOI: 10.1038/s41388-024-03228-5.

References

Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J . Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014; 5:75. PMC: 3942647. DOI: 10.3389/fphys.2014.00075. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Kenny H, Kaur S, Coussens L, Lengyel E . The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008; 118(4):1367-79. PMC: 2267016. DOI: 10.1172/JCI33775. View

Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly E, Li J . Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunol Res. 2016; 5(1):17-28. PMC: 5215959. DOI: 10.1158/2326-6066.CIR-16-0206. View

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

Ostrand-Rosenberg S, Sinha P, Beury D, Clements V . Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012; 22(4):275-81. PMC: 3701942. DOI: 10.1016/j.semcancer.2012.01.011. View

Larsen A, Kuczek D, Kalvisa A, Siersbaek M, Thorseth M, Johansen A . Collagen Density Modulates the Immunosuppressive Functions of Macrophages. J Immunol. 2020; 205(5):1461-1472. DOI: 10.4049/jimmunol.1900789. View

Cole K, Al-Kadhimi Z, Talmadge J . Role of myeloid-derived suppressor cells in tumor recurrence. Cancer Metastasis Rev. 2023; 42(1):113-142. PMC: 9840433. DOI: 10.1007/s10555-023-10079-1. View

10.

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

11.

Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G . Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003; 63(17):5224-9. View

12.

Kim R, Hashimoto A, Markosyan N, Tyurin V, Tyurina Y, Kar G . Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature. 2022; 612(7939):338-346. PMC: 9875862. DOI: 10.1038/s41586-022-05443-0. View

13.

Gerstberger S, Jiang Q, Ganesh K . Metastasis. Cell. 2023; 186(8):1564-1579. PMC: 10511214. DOI: 10.1016/j.cell.2023.03.003. View

14.

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

15.

Griffin R, Williams B, Wild R, Cherrington J, Park H, Song C . Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002; 62(6):1702-6. View

16.

Aoki M, Kanamori M, Ohmori K, Takaishi M, Huh N, Nogami S . Expression of developmentally regulated endothelial cell locus 1 was induced by tumor-derived factors including VEGF. Biochem Biophys Res Commun. 2005; 333(3):990-5. DOI: 10.1016/j.bbrc.2005.06.009. View

17.

Tu J, Xu H, Ma L, Li C, Qin W, Chen X . Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022; 12(2):747-766. PMC: 8692903. DOI: 10.7150/thno.65828. View

18.

Chen X, Kang R, Kroemer G, Tang D . Targeting ferroptosis in pancreatic cancer: a double-edged sword. Trends Cancer. 2021; 7(10):891-901. DOI: 10.1016/j.trecan.2021.04.005. View

19.

Jin J, Xie Y, Zhang J, Wang J, Dai S, He W . Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023; 67:100929. DOI: 10.1016/j.drup.2023.100929. View

20.

Motzer R, Alekseev B, Rha S, Porta C, Eto M, Powles T . Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384(14):1289-1300. DOI: 10.1056/NEJMoa2035716. View